Intangible Assets, net (Tables)

12 Months Ended

Dec. 31, 2014

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of Intangible Assets, net

($ amounts in thousands)

	December 31, 2014							December 31, 2013
	(Successor)							(Successor)
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Developed products (1)	$	957,166	$	(373,602	)	$	583,564	$	878,607	$	(204,218	)	$	674,389
Other product related royalty streams	115,600		(37,334		)	78,266		115,600		(22,709		)	92,891
IPR&D (2)	351,614		—			351,614		298,100		—			298,100
Trade names (3)	27,100		(118		)	26,982		26,400		—			26,400
Other	1,153		(826		)	327		1,000		(132		)	868
	$	1,452,633	$	(411,880	)	$	1,040,753	$	1,319,707	$	(227,059	)	$	1,092,648

(1) Developed products include intangible assets related to commercial products as part of the Merger, subsequently developed IPR&D, products acquired from the Watson/Actavis Merger, and intangible assets related to commercial products as part of the Par Sterile Acquisition. These products are amortized based on its remaining useful life.

(2) IPR&D indefinite-lived assets include IPR&D as part of the Merger, IPR&D acquired from the Watson/Actavis Merger, and IPR&D acquired as part of the Par Sterile Acquisition.

(3) Trade names include Par and Par Sterile Acquisition related trade name. The Par Sterile Acquisition related trade name is being amortized over its useful life, while the Par trade name is treated as an indefinite-lived asset and is not amortized.

Schedule of Future Amortization Expense

The following table does not include estimated amortization expense for future milestone payments that may be paid and result in the creation of intangible assets after December 31, 2014 and assumes the intangible asset related to the Par trade name as an indefinite lived asset will not be amortized in the future.

($ amounts in thousands)

	Estimated Amortization Expense
2015	155,188
2016	150,649
2017	170,569
2018	135,113
2019	112,770
2020 and thereafter	290,064
		$1,014,353